Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CY150112 in Healthy Chinese Subjects
NCT04839926Phase 1Unknown
- Sponsor
- Jiangsu Nhwa Pharmaceutical
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CY150112 in schizophrenia (6 cohorts), sponsored by Jiangsu Nhwa Pharmaceutical. Primary endpoint: Incidence of Adverse Events. Status: unknown.
02
Drugs
CY150112
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04839926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04839926.